Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)4.10bn
- Net income in USD998.12m
- Incorporated2019
- Employees6.13k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
Acquired company | 22UA:GER since announced | Transaction value |
---|---|---|
AexeRNA Therapeutics LLC | -3.29% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics Inc | 1.24bn | -535.98m | 11.96bn | 1.31k | -- | 13.90 | -- | 9.62 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Medpace Holdings Inc | 1.96bn | 312.32m | 12.08bn | 5.80k | 39.72 | 17.94 | 35.53 | 6.15 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Viatris Inc | 15.43bn | 54.70m | 13.62bn | 38.00k | 270.97 | 0.6729 | 4.87 | 0.883 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.86bn | 1.40k | 56.66 | 6.09 | 51.13 | 7.34 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 15.59bn | 3.40k | 77.78 | 3.07 | 50.18 | 6.31 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 1.83bn | -440.24m | 18.10bn | 2.10k | -- | -- | -- | 9.90 | -3.59 | -3.59 | 14.46 | -1.75 | 0.4957 | 2.85 | 8.43 | 870,615.30 | -11.94 | -26.56 | -15.61 | -32.77 | 83.02 | 83.66 | -24.08 | -94.26 | 2.99 | -2.11 | 1.28 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
BioNTech SE - ADR | 4.10bn | 998.12m | 20.61bn | 6.13k | 21.07 | 0.949 | 17.25 | 5.03 | 4.12 | 4.12 | 16.97 | 91.37 | 0.165 | 1.50 | 0.8207 | 668,093.90 | 4.02 | 37.91 | 4.51 | 44.76 | 84.29 | 83.82 | 24.36 | 50.36 | 9.26 | -- | 0.0107 | 4.73 | -77.94 | 97.35 | -90.14 | -- | 60.06 | -- |
ICON PLC | 8.23bn | 683.12m | 24.76bn | 41.10k | 36.41 | 2.63 | 19.44 | 3.01 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Biogen Inc | 9.66bn | 1.17bn | 29.43bn | 7.57k | 25.30 | 1.94 | 17.34 | 3.05 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 31 Dec 2023 | 8.69m | 3.66% |
PRIMECAP Management Co.as of 31 Dec 2023 | 4.76m | 2.00% |
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 2023 | 4.52m | 1.90% |
Harding Loevner LPas of 31 Dec 2023 | 3.94m | 1.66% |
Flossbach von Storch AGas of 31 Dec 2023 | 3.55m | 1.49% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 1.37m | 0.58% |
UBS Asset Management Switzerland AGas of 31 Dec 2023 | 979.07k | 0.41% |
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 938.75k | 0.40% |
Altrinsic Global Advisors LLCas of 31 Dec 2023 | 754.39k | 0.32% |
Quinn Opportunity Partners LLCas of 31 Dec 2023 | 674.58k | 0.28% |